Previous 10 | Next 10 |
Summary This portfolio strategy uses the quarterly 13F filings to extract 50 consensus stocks from 40 large hedge funds that have more than $3.5 billion in Assets Under Management. From 1/2/2016 to date investing in all 50 stocks, equally weighted, would have produced a total retu...
The US FDA has approved Incyte's ( NASDAQ: INCY ) Pemazyre (pemigatinib) for the treatment of adults with relapsed or refractory myeloid/lymphoid neoplasms (MLNs) with FGFR1 rearrangement. The selective fibroblast growth factor receptor (FGFR) inhibitor was approv...
– T his marks the second indication for Pemazyre, which received accelerated FDA approval in 2020 for adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or other rearra...
Incyte (Nasdaq:INCY) today announced that multiple abstracts featuring data from its dermatology portfolio will be presented at the upcoming 2022 European Academy of Dermatology and Venereology (EADV) Congress, held September 7-10, 2022, in Milan and virtually. “We are excite...
This portfolio strategy uses the quarterly 13F filings to extract 50 consensus stocks from 40 large hedge funds that have more than $3.5 billion Assets Under Management. After the Q1-2022 13F filings the consensus holdings were updated, 10 stocks were removed and 8 added from the univ...
Incyte Corporation (INCY) Q2 2022 Earnings Conference Call Augut 02, 2022 8:00 AM ET Company Participants Christine Chiou – Head of Investor Relations Hervé Hoppenot – Chairman, President and Chief Executive Officer Barry Flannelly – Exe...
Incyte ( NASDAQ: INCY ) saw its Q2 net income rise ~27% year over year to ~$226.4M as it beat on the top and bottom lines . Non-GAAP basic EPS of $1.02 compared to $0.81 in Q2 2021. Revenue of $911.4M was ~29% year-over-year increase. This was driven by a 13% incre...
The following slide deck was published by Incyte Corporation in conjunction with their 2022 Q2 earnings call. For further details see: Incyte Corporation 2022 Q2 - Results - Earnings Call Presentation
Incyte press release ( NASDAQ: INCY ): Q2 Non-GAAP EPS of $1.01 beats by $0.27 . Revenue of $911.4M (+29.1% Y/Y) beats by $93.15M . Jakafi net product revenue guidance range of $2.36B to $2.4B for 2022 (prior $2.33B - $2.4B). “The second quarter...
Total revenues increased 29% year-over-year (Y/Y) to $911 million; total product revenues of $664 million (+15% Y/Y) Jakafi ® (ruxolitinib) net product revenues of $598 million in Q2’22 (+13% Y/Y) driven by volume growth; raising the bottom end of full year g...
News, Short Squeeze, Breakout and More Instantly...
2024-07-12 10:12:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-07-02 11:40:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-07-02 06:15:05 ET BMO Capital analyst issues UNDERPERFORM recommendation for INCY on July 2, 2024 04:26AM ET. The previous analyst recommendation was Market Perform. INCY was trading at $60.87 at issue of the analyst recommendation. The overall analyst consensus : B...